NCT03894618: SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas

NCT03894618
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: MSI-H, DNA damage repair mutations
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have microsatellite instability high (MSI-H) or mismatch repair deficient (MMRD) solid tumors
Exclusions: Patients who have received more than two prior checkpoint inhibitor containing treatment regimens; Patients who had disease pregressions checkpoint inhibitor therapy defined as disease progression within 3 months of treatment initiation
https://ClinicalTrials.gov/show/NCT03894618

Comments are closed.

Up ↑